Vancomycin overuse in Siriraj Hospital

Journal of the Medical Association of Thailand

Volumn 89, Issue SUPPL. 5, 2006, Pages

  Rattanaumpawan, Pinyo ^a   Thamlikitkul, Visanu ^a   Chokepaibulkit, Kulkanya ^a   Lohsiriwat, Darin ^a   Aswapokee, Nalinee ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Anti bacterial agents; HICPAC recommendation; Prospective observational studies; Therapeutic use; Vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG COST; DRUG USE; ENTEROCOCCAL INFECTION; FEMALE; HOSPITAL DEPARTMENT; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OBSERVATIONAL STUDY; PROPHYLAXIS; THAILAND; TREATMENT OUTCOME; TREATMENT RESPONSE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PROSPECTIVE STUDIES; RISK FACTORS; THAILAND; VANCOMYCIN;

EID: 33846680367     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993; 42: 597-9.
2. Aswapokee A, Tiengrim S, Charoensook B, Sangsiriwut K. Resistant Enterococci: a decade difference. J Infect Dis Antimicrob Agents. 2000; 17: 7-11.
3. Nilgate S, Nunthapisud P, Chongthaleong A. Vancomycin-resistant enterococci in King Chulalongkorn Memorial Hospital: a 5-year study. J Med Assoc Thai 2003; 86(Suppl 2): S224-9.
4. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 72: 195-8.
5. Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagan SE, et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 2003; 302: 1569-71.
6. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36: 429-39.
7. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 39: 539-45.
8. Dunne WM Jr, Qureshi H, Pervez H, Nafziger DA. Staphylococcus epidermidis with intermediate resistance to vancomycin: elusive phenotype or laboratory artifact? Clin Infect Dis 2001; 33: 135-7.
9. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12 (Suppl 1): 16-23.
10. Cormican MG, Jones RN. Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci. Drugs 1996; 51 (Suppl 1): 6-12.
11. Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362-86.
12. Hamilton CD, Drew R, Janning SW, Latour JK, Hayward S. Excessive use of vancomycin: a successful intervention strategy at an academic medical center. Infect Control Hosp Epidemiol 2000; 21: 42-5.
13. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol 1995; 16: 105-13.
14. Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines. Infect Control Hosp Epidemiol 1996; 17: 356-9.
15. Jarvis WR. Epidemiology, appropriateness, and cost of vancomycin use. Clin Infect Dis 1998; 26: 1200-3.
16. Drori-Zeides T, Raveh D, Schlesinger Y, Yinnon AM. Practical guidelines for vancomycin usage, with prospective drug-utilization evaluation. Infect Control Hosp Epidemiol 2000; 21: 45-7.
17. Hopkins HA, Sinkowitz-Cochran RL, Rudin BA, Keyserling HL, Jarvis WR. Vancomycin use in pediatric hematology-oncology patients. Infect Control Hosp Epidemiol 2000; 21: 48-50.
18. Kumana CR, Ching TY, Kong Y, Ma EC, Kou M, Lee RA, et al. Curtailing unnecessary vancomycin usage in a hospital with high rates of methicillin resistant Staphylococcus aureus infections. Br J Clin Pharmacol 2001; 52: 427-32.
19. Evans ME, Millheim ET, Rapp RP. Vancomycin use in a university medical center: effect of a vancomycin continuation form. Infect Control Hosp Epidemiol 1999; 20: 417-20.
20. de Castro MS, Kopittke L, Fuchs FD, Tannhauser M. Evidence of inappropriate use of vancomycin in a university affiliated hospital in Brazil. Pharmacoepidemiol Drug Saf 1999; 8: 405-11.
21. Goodman DF, Gottsch JD. Methicillin-resistant Staphylococcus epidermidis keratitis treated with vancomycin. Arch Ophthalmol 1988; 106: 1570-1.
22. Gordon YJ. Vancomycin prophylaxis and emerging resistance: are ophthalmologists the villains? The heroes? Am J Ophthalmol 2001; 131: 371-6.
23. Flynn HW Jr, Scott IU, Brod RD, Han DP. Current mnagement of edophthalmitis: the endophthalmitis vitrectomy study. Contemp Ophthalmology 2005; 4: 1-6.
24. Cahane M, Ben Simon GJ, Barequet IS, Grinbaum A, Diamanstein-Weiss L, Goller O, et al. Human corneal stromal tissue concentration after consecutive doses of topically applied 3.3% vancomycin. Br J Ophthalmol 2004; 88: 22-4.
25. Mekvivatanawong S, Srifuengfung S, Chokepaibulkit S, Lohsiriwat D, Thamlikitkul V. Prevalence of infections caused by community-acquired methicillin-resistant Staphylococcus aureus at Siriraj Hospital, Bangkok, Thailand. Bangkok; Faculty of Medicine Siriraj Hospital; 2006.
26. Fang CT, Shau WY, Hsueh PR, Chen YC, Wang JT, Hung CC, et al. Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome. J Antimicrob Chemother 2006; 57: 511-9.
27. Kim SH, Park WB, Lee KD, Kang CI, Bang JW, Kim HB, et al. Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004; 54: 489-97.
28. Roghmann MC. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia. Arch Intern Med 2000; 160: 1001-4.
29. Bestul MB, Vandenbussche HL. Antibiotic lock technique: review of the literature. Pharmacotherapy 2005; 25: 211-27.